Rep. April McClain Delaney Purchases Shares of Labcorp Holdings Inc. (NYSE:LH)

Representative April McClain Delaney (D-Maryland) recently bought shares of Labcorp Holdings Inc. (NYSE:LH). In a filing disclosed on November 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in Labcorp stock on October 31st.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Teledyne Technologies (NYSE:TDY) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 10/29/2025.
• Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/29/2025.
• Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 10/29/2025.
• Sold $1,001 – $15,000 in shares of Middleby (NASDAQ:MIDD) on 10/22/2025.
• Purchased $15,001 – $50,000 in shares of Nasdaq (NASDAQ:NDAQ) on 10/22/2025.
• Purchased $1,001 – $15,000 in shares of Bio-Techne (NASDAQ:TECH) on 10/22/2025.

Labcorp Price Performance

Labcorp stock opened at $245.96 on Friday. The stock has a market capitalization of $20.39 billion, a price-to-earnings ratio of 24.16, a PEG ratio of 1.59 and a beta of 0.91. Labcorp Holdings Inc. has a 52-week low of $209.38 and a 52-week high of $293.72. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.55. The stock’s 50 day moving average price is $274.80 and its two-hundred day moving average price is $261.87.

Labcorp (NYSE:LH) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $4.18 earnings per share for the quarter, beating the consensus estimate of $4.13 by $0.05. The company had revenue of $3.56 billion during the quarter, compared to analyst estimates of $3.56 billion. Labcorp had a net margin of 6.21% and a return on equity of 15.85%. Labcorp’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.50 EPS. Labcorp has set its FY 2025 guidance at 16.150-16.500 EPS. On average, equities analysts predict that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.

Labcorp Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 11th. Shareholders of record on Wednesday, November 26th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Wednesday, November 26th. This represents a $2.88 annualized dividend and a yield of 1.2%. Labcorp’s payout ratio is 28.29%.

Insider Transactions at Labcorp

In other news, Director Richelle P. Parham sold 7,009 shares of Labcorp stock in a transaction on Friday, October 31st. The stock was sold at an average price of $254.28, for a total value of $1,782,248.52. Following the completion of the transaction, the director directly owned 2,469 shares in the company, valued at approximately $627,817.32. The trade was a 73.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 3,903 shares of the business’s stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $271.42, for a total value of $1,059,352.26. Following the sale, the executive vice president owned 2,274 shares in the company, valued at approximately $617,209.08. The trade was a 63.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,555 shares of company stock valued at $4,347,040 over the last three months. Company insiders own 0.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on LH shares. Mizuho increased their price objective on shares of Labcorp from $285.00 to $320.00 and gave the stock an “outperform” rating in a research report on Friday, October 17th. Barclays lifted their price target on shares of Labcorp from $275.00 to $290.00 and gave the company an “equal weight” rating in a research report on Thursday, October 2nd. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. HSBC lowered shares of Labcorp from a “buy” rating to a “hold” rating and set a $260.00 price objective on the stock. in a research note on Thursday, July 10th. Finally, UBS Group reduced their price objective on shares of Labcorp from $325.00 to $320.00 and set a “buy” rating for the company in a report on Wednesday, October 29th. Eleven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $295.54.

Institutional Trading of Labcorp

A number of hedge funds have recently bought and sold shares of LH. Ameritas Advisory Services LLC purchased a new position in shares of Labcorp in the third quarter worth about $119,000. Public Sector Pension Investment Board boosted its holdings in Labcorp by 10.8% in the 3rd quarter. Public Sector Pension Investment Board now owns 7,168 shares of the medical research company’s stock worth $2,058,000 after buying an additional 696 shares during the period. Illinois Municipal Retirement Fund grew its stake in Labcorp by 12.5% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 54,684 shares of the medical research company’s stock valued at $15,698,000 after buying an additional 6,094 shares in the last quarter. Cibc World Market Inc. raised its holdings in Labcorp by 5.2% during the 3rd quarter. Cibc World Market Inc. now owns 3,145 shares of the medical research company’s stock valued at $903,000 after acquiring an additional 155 shares during the period. Finally, Caprock Group LLC bought a new stake in Labcorp during the 3rd quarter valued at $1,045,000. 95.94% of the stock is currently owned by institutional investors.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Labcorp Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.